Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

Authors: Jeffrey A. Cohen, Gıancarlo Comı, Krzysztof Selmaj, Amit Bar‐Or, Douglas L. Arnold, Lawrence Steinman, Hans‐Peter Hartung, Xavier Montalbán, Eva Havrdová, Bruce Cree, James K. Sheffield, Neil Minton, Kartik Raghupathi, Vivian Huang, Ludwig Kappos - The Lancet 2019 cited by 279